^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    NEXI-003

    i
    Other names: NEXI-003
    Associations

    News

    Trials
    Company:
    NexImmune
    Drug class:
    Survivin inhibitor, HPV-16 E6 protein inhibitor, HPV-16 E7 protein inhibitor, CD8 T-cell agonist, HPV-18 E6 protein inhibitor, HPV-18 E7 protein inhibitor
    Related drugs:
    Associations

    News

    Trials
    10ms
    Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers (clinicaltrials.gov)
    P1, N=36, Not yet recruiting, NexImmune Inc. | Trial completion date: Aug 2025 --> Aug 2027 | Trial primary completion date: Jul 2024 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    cyclophosphamide • fludarabine IV • NEXI-003
    almost2years
    Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers (clinicaltrials.gov)
    P1, N=36, Not yet recruiting, NexImmune Inc. | Initiation date: Dec 2022 --> Mar 2023
    Trial initiation date
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • CD4 (CD4 Molecule)
    |
    cyclophosphamide • fludarabine IV • NEXI-003
    2years
    Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers (clinicaltrials.gov)
    P1, N=36, Not yet recruiting, NexImmune Inc.
    New P1 trial
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • CD4 (CD4 Molecule)
    |
    cyclophosphamide • fludarabine IV • NEXI-003